NASDAQ:NTBL Notable Labs (NTBL) Stock Price, News & Analysis → Have You Seen Elon’s New A.I. Device? (Picture Inside) (From InvestorPlace) (Ad) Free NTBL Stock Alerts $0.91 -0.01 (-1.08%) (As of 05/1/2024 ET) Add Compare Share Share Today's Range$0.86▼$0.9850-Day Range$0.91▼$1.9152-Week Range$0.83▼$11.20Volume100,950 shsAverage Volume65,664 shsMarket Capitalization$2.03 millionP/E RatioN/ADividend YieldN/APrice Target$8.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial Media Get Notable Labs alerts: Email Address Notable Labs MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside775.2% Upside$8.00 Price TargetShort InterestHealthy0.02% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.50Based on 2 Articles This WeekInsider TradingN/AProj. Earnings GrowthN/ASee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.21 out of 5 stars 3.5 Analyst's Opinion Consensus RatingNotable Labs has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageNotable Labs has only been the subject of 2 research reports in the past 90 days. Previous Next 5.0 Short Interest Percentage of Shares Shorted0.02% of the float of Notable Labs has been sold short.Short Interest Ratio / Days to CoverNotable Labs has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Notable Labs has recently decreased by 51.42%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldNotable Labs does not currently pay a dividend.Dividend GrowthNotable Labs does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for NTBL. Previous Next 3.1 News and Social Media Coverage News SentimentNotable Labs has a news sentiment score of 0.50. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.33 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Notable Labs this week, compared to 1 article on an average week.Search InterestOnly 1 people have searched for NTBL on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.MarketBeat Follows5 people have added Notable Labs to their MarketBeat watchlist in the last 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Notable Labs insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 1.20% of the stock of Notable Labs is held by insiders.Percentage Held by Institutions70.48% of the stock of Notable Labs is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of Notable Labs is -0.25, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Notable Labs is -0.25, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioNotable Labs has a P/B Ratio of 0.13. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Porter & CompanyTrump’s last act as President You’ve probably never heard of Executive Order #13972. Signed by President Trump just days before leaving office, it greenlit what could be the most revolutionary technology of the decade… yet it has nothing to do with AI, blockchain, or mRNA vaccines. For the full story, click here. About Notable Labs Stock (NASDAQ:NTBL)Notable Labs, Ltd., a clinical-stage platform therapeutics company, engages in developing predictive precision medicines for patients with cancer. The company, through its proprietary Predictive Precision Medicines Platform (PPMP), bio-simulates a cancer treatment and predicts, whether or not the patient is likely to respond to that specific therapeutic. Its PPMP is designed to identify and select clinically responsive patients prior to their treatment and thus fast-track clinical development in this patient population. The company's pipeline includes Volasertib, a potent Polo-like kinase 1 (PLK-1) inhibitor for acute myeloid leukemia (AML), pediatric leukemia, and myelodysplastic syndromes indications; and Fosciclopirox, a pro-drug of ciclopirox for AML. Notable Labs, Ltd. is headquartered in Foster City, California.Read More NTBL Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart NTBL Stock News HeadlinesApril 30, 2024 | seekingalpha.comNTBL Notable Labs, Ltd.April 16, 2024 | msn.comCisco To Rally Around 24%? Here Are 10 Top Analyst Forecasts For MondayMay 2, 2024 | Porter & Company (Ad)The biggest energy story ever? Discover why I’m calling this one of the biggest developments in the global energy market since the shale revolution… why everything you’ve ever been told about Trump’s environmental record is a lie…April 15, 2024 | markets.businessinsider.comBuy Rating for Notable Labs: Financial Stability and Strategic Advances in AML Clinical TrialsApril 12, 2024 | investorplace.comNTBL Stock Earnings: Notable Labs Misses EPS for Q4 2023April 12, 2024 | globenewswire.comNotable Labs Reports 2023 Financial Results and Provides a Business UpdateApril 10, 2024 | investing.comNotable Labs advances cancer treatment with cryopreserved samplesApril 9, 2024 | globenewswire.comNotable Labs Presents the Design Plan for the PPMP-Enabled Phase 2 Trial with Volasertib for Relapsed/Refractory AML at AACR 2024May 2, 2024 | Porter & Company (Ad)The biggest energy story ever? Discover why I’m calling this one of the biggest developments in the global energy market since the shale revolution… why everything you’ve ever been told about Trump’s environmental record is a lie…April 8, 2024 | globenewswire.comNotable Labs Presentation of Data Related to Innovations in the Use of Cryopreserved Samples in the PPMP Assay at AACR 2024 Expands the Potential of the PlatformMarch 5, 2024 | globenewswire.comNotable Labs to Present Two Posters at AACR 2024 on PPMP PlatformMarch 5, 2024 | globenewswire.comNotable Labs to Present Two Posters at AACR 2024 on PPMP PlatformFebruary 22, 2024 | finance.yahoo.comNotable Advances Volasertib Phase 2 Program Utilizing Proprietary Predictive Precision Medicine Platform-Guided EnrollmentFebruary 22, 2024 | globenewswire.comNotable Advances Volasertib Phase 2 Program Utilizing Proprietary Predictive Precision Medicine Platform-Guided EnrollmentDecember 21, 2023 | markets.businessinsider.comMaintained Buy Rating on Notable Labs with Adjusted Price Target Amid Drug Setback and PPMP Platform PotentialDecember 18, 2023 | finance.yahoo.comNotable Reports Predictive Precision Medicine Platform (PPMP) Accurately Predicted Fosciclopirox Trial OutcomeDecember 18, 2023 | finance.yahoo.comNotable Reports Predictive Precision Medicine Platform (PPMP) Accurately Predicted Fosciclopirox Trial OutcomeDecember 14, 2023 | investing.comNotable Labs Ltd (NTBL)December 13, 2023 | finance.yahoo.comNotable Labs Donates $60,000 to MDS Foundation to Accelerate Progress for Patients with Myelodysplastic SyndromesDecember 11, 2023 | finance.yahoo.comNotable Labs Funds Myelodysplastic Syndromes Foundation with $60,000 GrantDecember 4, 2023 | finance.yahoo.comNotable Labs to Participate in JMP Securities Hematology and Oncology SummitNovember 29, 2023 | morningstar.comNotable Labs Ltd NTBLNovember 21, 2023 | markets.businessinsider.comKeay Nakae’s Buy Rating on Notable Labs: Predictive Precision Medicine Platform and Financial Stability as Key FactorsNovember 16, 2023 | washingtonpost.comNotable Labs: Q3 Earnings SnapshotNovember 16, 2023 | finance.yahoo.comNotable Labs Announces Filing of Form 10-Q for Third Quarter 2023See More Headlines Receive NTBL Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Notable Labs and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Today5/02/2024Next Earnings (Estimated)5/20/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:NTBL Previous SymbolNASDAQ:NTBL CUSIPN/A CIK1603207 Webwww.vblrx.com Phone(728) 993-5000Fax972-8993-5001Employees13Year FoundedN/APrice Target and Rating Average Stock Price Target$8.00 High Stock Price Target$9.00 Low Stock Price Target$7.00 Potential Upside/Downside+775.2%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($3.6270) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-11,260,000.00 Net MarginsN/A Pretax Margin-3,633.55% Return on Equity-62.07% Return on Assets-48.32% Debt Debt-to-Equity Ratio0.02 Current Ratio5.65 Quick Ratio5.65 Sales & Book Value Annual Sales$310,000.00 Price / Sales6.55 Cash FlowN/A Price / Cash FlowN/A Book Value$6.81 per share Price / Book0.13Miscellaneous Outstanding Shares2,220,000Free Float2,193,000Market Cap$2.03 million OptionableNo Data Beta0.77 20 Stocks to Sell NowMarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.Get This Free Report Key ExecutivesMr. Scott Alan McPherson CFE (Age 63)CPA, CVA, Chief Financial Officer Comp: $412.89kDr. Glenn C. Michelson M.D.Chief Medical OfficerKey CompetitorsClearmind MedicineNASDAQ:CMNDBiodexa PharmaceuticalsNASDAQ:BDRXBio-PathNASDAQ:BPTHDermata TherapeuticsNASDAQ:DRMAQualigen TherapeuticsNASDAQ:QLGNView All CompetitorsInsiders & InstitutionsIndustry Ventures L.L.C.Bought 204,424 shares on 2/6/2024Ownership: 9.208%Fr Capital Holdings, L.P.Sold 50,000 sharesTotal: $94,500.00 ($1.89/share)Fr Capital Holdings, L.P.Sold 11,456 sharesTotal: $24,744.96 ($2.16/share)Fr Capital Holdings, L.P.Sold 2,867 sharesTotal: $7,196.17 ($2.51/share)View All Insider TransactionsView All Institutional Transactions NTBL Stock Analysis - Frequently Asked Questions Should I buy or sell Notable Labs stock right now? 2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Notable Labs in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" NTBL shares. View NTBL analyst ratings or view top-rated stocks. What is Notable Labs' stock price target for 2024? 2 Wall Street analysts have issued 12-month price targets for Notable Labs' shares. Their NTBL share price targets range from $7.00 to $9.00. On average, they anticipate the company's share price to reach $8.00 in the next twelve months. This suggests a possible upside of 775.2% from the stock's current price. View analysts price targets for NTBL or view top-rated stocks among Wall Street analysts. How have NTBL shares performed in 2024? Notable Labs' stock was trading at $1.89 at the beginning of 2024. Since then, NTBL stock has decreased by 51.6% and is now trading at $0.9140. View the best growth stocks for 2024 here. Are investors shorting Notable Labs? Notable Labs saw a decline in short interest in April. As of April 15th, there was short interest totaling 10,300 shares, a decline of 51.4% from the March 31st total of 21,200 shares. Based on an average daily volume of 86,500 shares, the short-interest ratio is currently 0.1 days. Approximately 0.0% of the company's stock are short sold. View Notable Labs' Short Interest. When is Notable Labs' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, May 20th 2024. View our NTBL earnings forecast. How do I buy shares of Notable Labs? Shares of NTBL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:NTBL) was last updated on 5/2/2024 by MarketBeat.com Staff From Our PartnersAI finds its first serious applicationWall Street StarA.I. is a Tidal Wave - Here’s What to BuyChaikin AnalyticsHave You Seen Elon’s New A.I. Device? (Picture Inside)InvestorPlaceHealthcare Takes A Big Step Forward With The Help Of AIThe Bull Report😱 This phenomenon is smashing regular market gainsMillPubDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsForget AI, Imperium Is Expected to Grow 320,00% in 3 YearsBanyan Hill PublishingPOTUS in ‘25 Not Biden/Trump, ButThe Freeport Society Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Notable Labs, Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
